$SNDK - One of the fascinating charts ever. It took almost a year to find its ATH (which itself was a record and wealth creator) now the rate it is coming down is unparalleled. No support at all. Let's see what happens in the next few days. We can only speculate. None of us know
3
694
$IBRX- $IBRX Short INTELLIGENCE REPORT: MARCH 23, 2026. As always data attached ( short interest data)
Today was not just a green day; it was a structural shift in $IBRX market mechanics. The "Short Trap" has moved from theory to reality.
1. THE TAPE: BREAKOUT & ABSORPTION
The Breach: $IBRX decisively cleared the $9.30 resistance, hitting an intraday high of $9.54.
The Whale Signature: A massive 695,962-share block hit at the $9.40 close ($6.5M+). This signals institutional "buy-in," not retail flipping.
Volume: 26.7M shares extreme conviction fueled by a "Wall of Analysts" (BTIG $13 target / D. Boral $23 target).
2. MECHANICAL FAILURE: SHORT EXHAUSTION
Utilization: Pinned at 100%. There is zero remaining "legal" inventory to borrow.
Inventory Crisis: IBKR availability dropped to a staggering 200 shares tonight. Shorts are out of ammo to defend the $10.00 magnet.
Borrow Fees: Averaging 11.25% (Max 13.14%). Shorts are paying predatory interest to stay underwater.
3. THE CATALYST CLOCK
FDA Window: Today is Day 14 since the sBLA resubmission. The market is betting on a Class 1 (60-day) designation, moving the finish line to May.
THE BOTTOM LINE: We closed at $9.40 (+11%) on massive volume. $9.30 is now the floor. With zero borrow and a Gamma Trap set, the path of least resistance is UP.
#IBRX #ANKTIVA #ShortSqueeze #Biotech
$IBRX- Marc 23rd UPDATE: THE $9.30 BATTLE IS HERE
$IBRX Family, listen up. We are at a structural "Breaking Point" today. While the broader market is distracted, the tape is revealing a massive tug-of-war for the soul of this stock.
The Situation: Shorts are Cornered
This morning, $IBRX gapped up and touched $9.38, officially blowing past Friday’s "options pin." Since then, we have seen aggressive "Short-Exempt" selling hitting the bid to keep us under the $9.30 mark.
Why are they so desperate?
100% Utilization: There are officially ZERO shares left to borrow (Ortex confirms only ~15k available). They are literally recycling the same "ghost shares" to suppress the price.
The $9.32 Wall: This was Friday's manipulation high. Breaking and holding above this level triggers a massive wave of mechanical stop-losses for the shorts.
The Catalyst: The "Wall of Analysts"
BTIG: Initiated with a BUY ($13 Target) this morning.
D. Boral (Jason Kolbert): Reaffirmed his $23.00 Target today.
The Message: The "Smart Money" is pricing this for a $10B+ valuation while the shorts are fighting over pennies at $9.15.
The Game Plan
The shorts are "leaning" on the $9.17–$9.30 wall. They are hoping you get bored and sell. Don't.
Watch $9.00: This has become a massive institutional support floor.
Watch the Break: If we clear $9.40 on high volume this afternoon, the "Squeeze" moves from a theory to a reality.
Bottom Line: We have the science, the revenue (Saudi/Macau), and the analyst upgrades. The shorts only have a 14,000-share wall at $9.17. That wall is made of paper.
Patience is the only thing they can’t beat.
#IBRX #ANKTIVA #ShortSqueeze
$IBRX- $IBRX Forensic Catalyst Calendar: March 22–28
As always not financial advise .. but presenting facts based on publicly available data.
1/ Sunday–Tuesday (March 22–24): The ROTH Conference 🎤
The Event: 38th Annual ROTH Conference in Dana Point, CA.
The Data: ImmunityBio management is confirmed to participate in 1-on-1 institutional meetings and a presentation.
The Analysis: This is the first time management will speak publicly since the Macau approval (Friday) and the NCCN Guideline expansion (Tuesday). Watch for updates on international launch timelines and the sBLA review status. Institutional "Smart Money" often accumulates following these private fireside chats.
2/ Monday (March 23): The "Pin Release" & Gap-Up Potential
The Mechanical Event: First trading day following the March monthly options expiration.
The Analysis: On Friday, the stock was pinned at $8.47 to save Market Makers from delivering 3M+ shares for the $9.00 calls. That financial incentive is now zero. Without the artificial "Operational Shorting" pressure, $IBRX is free to react to the Macau Asia-entry news.
Watch Level: A break of $9.32 (Friday's high) would signal a complete shift in control from shorts to bulls.
3/ Tuesday–Thursday (March 24–26): The "Saudi 30-Day" Window 🇸🇦
The Commercial Event: Mid-point of the 60-day launch window established on February 20, 2026.
The Analysis: We are officially entering the "Pre-Launch" phase for Saudi Arabia.
The Catalyst: Any news regarding the first shipment of ANKTIVA to Cigalah Healthcare or the registration of the first KSA patient would be a massive "Proof of Concept" for international revenue. Remember: Saudi is the only place approved for Lung Cancer (NSCLC) right now a market much larger than bladder cancer.
4/ All Week: FDA sBLA Acceptance Notification.The Regulatory Event: The 14–30 day window for the FDA to formally "Accept for Filing" the papillary-only sBLA resubmitted on March 9, 2026.
The Analysis: The FDA has already acknowledged receipt. A formal "Acceptance" PR next week would include the PDUFA date (the final decision deadline). This is a massive de-risking event that shorts are dreading.
5/ All Week: The NCCN "Silent Revenue" Build 🩺
The Guideline Event: First full week of clinical availability under the March 17 NCCN update.
The Analysis: Urologists across the US now have the green light (Category 2A) to prescribe ANKTIVA for papillary-only patients with high-confidence insurance reimbursement. This is "off-label" revenue starting immediately, effectively tripling the drug's US market size before the FDA even finishes its review.
Summary for Next Week:
The Situation: Shorts doubled down on Friday to pin the price, but they are now facing a week with zero options protection and four massive fundamental catalysts.
Monday is a new game. The Asia gateway is open, the Saudi launch is weeks away, and the US market just tripled in size. Data > Emotion. 🚀🚀
#IBRX #ANKTIVA #ShortSqueeze #BiotechInvesting #DrPSS #SaudiArabia
$IBRX- $IBRX Short Intelligence report- March 21st . Data attached. $IBRX is currently one of the most structurally over-leveraged shorts in the entire market.
1/ Numbers don’t lie, but they do tell a story. While we were all distracted by the Friday "pin" at $8.47, the short data was recording a catastrophic structural trap. Here is the forensic deep-dive into the current $IBRX Short Interest. #IBRX #ShortSqueeze #Ortex
2/ The "Supply Lock" (Utilization: 100%) -The Ortex data confirms we are at 100% Utilization.
What it means: Every single share available to be lent out has already been borrowed.
The Reality: There is zero legal borrow left. Any "selling" we saw at the $9.30 wall on Friday was almost certainly "Operational Shorting" (IOUs) by Market Makers. They are digging a hole they can't fill.
3/ The Magnitude: 132 Million Shares Trapped
Estimated Short Interest: 132.32 Million shares.
% of Freefloat on Loan: A massive 51.22%.
Short % of Freefloat: 34.87%.
Comparison: Anything over 20% is a powder keg. At 51% of the float on loan, $IBRX is currently one of the most structurally over-leveraged shorts in the entire market.
4/ Days to Cover (DTC): The "Week-Long Stampede"
DTC: 3.84 to 5.64 days (based on 3-month volume).
Translation: If every short seller tried to exit on Monday, it would take nearly 6 full days of 100% of the trading volume just to close their positions. There is no "Emergency Exit." In a squeeze, it becomes a literal stampede.
5/ Cost to Borrow (CTB) & Availability
CTB Average: 10.64%.
Availability: Interactive Brokers (IBKR) shows only 650k shares available at an 8.16% rate.
This is the "calm before the storm." With 100% utilization, the moment the price crosses $9.15, the CTB is mathematically primed to explode as lenders recall shares.
6/ The Verdict: The Friday "Pin" was a desperate defensive move. The shorts spent millions on Friday to force an $8.47 close and kill the $9.00 calls. But look at the Ortex charts—they didn't cover. They doubled down.
They are now "Naked" against: ✅ Macau/Asia Approval (New Revenue) ✅ NCI Science Validation (Govt Backing) ✅ 100% Supply Lock (No Exit)
The spring is coiled. The exit is blocked. Monday is a new game.
#ImmunityBio #ANKTIVA #ShortSqueeze #TradingData #Fintel
$IBRX- Another tough day on Friday ( March 20th). Second time in a week we tried to breach $9.30.. but could not hold on. Begs the question why.?. Here is a data driven explanation:
$IBRX Forensic Audit – The Friday "Pin" Exposed
1/ The "Friday Flush" wasn't a sell-off. It was a surgical strike. If you’re shaken by $IBRX dropping from $9.32 to $8.47, you’re looking at the wrong data. We have spent the morning digging through various platforms to understand the underlying data. Here is the "Smoking Gun" evidence of what really happened. #IBRX #ShortSqueeze
2/ The $9.00 "Call Wall" . There were 27,672 Call contracts sitting at the $9.00 strike for Friday's expiration.
The Math: If $IBRX closed at $9.01, Market Makers (MMs) would have been forced to buy/deliver 2.76 Million shares.
The Conclusion: Dropping the price to $8.47 saved the MMs millions. This wasn't a lack of buyers; it was a "Pin" to protect the house.
3/ Visible Manipulation. The Heatmap doesn't lie. Every time we touched $9.32, a massive "Orange Wall" appeared.
The 885K Block: Data confirms MMs dumped 885,000 shares at $9.26.
At 100% Utilization, these aren't real shares being sold—this is "Operational Shorting" used as a fire extinguisher to put out a fundamental rally.
4/ The Inst.itutional Floor. While retail was "shook" by the red candles,Thick bands of liquidity (buying) held the $8.40 - $8.50 line all afternoon.
Hidden Accumulation: While MMs were flushing the price to kill the options, "Whales" were sitting at the bid, vacuuming up every share being dumped.
5/ The "Bear" Trap .Don't be fooled by technical models calling for "Zero Probability" of upside.
The Flaw: Models using RSI and CMF are Lagging Indicators. They tell you what happened yesterday.
The Reality: They cannot calculate for Macau FDA Approval or NCI Science Validation. The news was suppressed by the options pin. The move is DELAYED, not canceled.
6/ The Verdict .We are looking at the literal friction between a company moving toward its true value and a financial system trying to settle its debts.
Short Interest: 132M+ shares.
Utilization: 100%.
Catalysts: Global.
The $9.00 "Options Anchor" is now gone. Monday is a new game. Data > Emotion.
#ImmunityBio #ANKTIVA #Biotech #ShortSqueeze
$IBRX- IBRX Dark Pool Intelligence Report – March 18, 2026 ( This is a tough one to write as all the data is not readily available.. So there may be errors here.. But here is our best shot. If someone has better data please share and we can analyze)
This is our 5th and final report for the night. If you missed our earlier deep-dives on Science, Options, Shorts, or Technicals, check the feed. Now, let’s look at the "Hidden" institutional tape. $IBRX
1/ Off-Exchange Volume Spike. Today, 54.2% of total volume was executed off-exchange (Dark Pools).
The Forensic Read: This confirms that more than half of the day's activity was institutional "Whales" filling large blocks away from the public eye. They are positioning heavily ahead of the next catalyst wave.
2/ Dark Pool Net Position (DPNP) -The DPNP for today finished at +$12.4M (Bullish).
Translation: Despite the midday price chop, there was a net "Buy" imbalance in the shadows. Institutions are absorbing the shares that shorts are "naked selling" to defend the $9.00 wall.
3/ Verify the Data (For the Skeptics) -we track the tape in real-time so you don’t have to, but we always encourage independent verification. You can check the aggregate off-exchange volume yourself.
Review the weekly/daily aggregates. (Note: Official FINRA public data has a reporting delay; our real-time reports utilize professional TRF feeds to catch these prints the second they hit.)
The Verdict: The whales are positioned. The science is validated. The shorts are out of ammo. The technicals are coiled. The dark pools are net-long.
The data across all 5 reports has converged. See you at the opening bell.
$IBRX- $IBRX Technical Intelligence Report – March 18, 2026
Price action doesn't lie. The $IBRX chart is screaming "Accumulation" as we head into the most critical 48 hours of the year. Here is the technical breakdown. $IBRX. Charts included.
1/ The Daily Setup (Coiling for Breakout)- The Daily chart shows a textbook "Higher Low" formation at $7.81. We are currently trading above the 20-day and 50-day EMA, which have now curved upward to provide a "Launchpad" support zone. The price is being compressed between the $8.40 support and the $9.00 resistance.
2/ Volume Analysis. Notice the "Bullish Divergence" in volume. Sell volume is drying up on red days, while green candles are seeing aggressive "Buying Spikes." This confirms that institutions are absorbing every share the shorts are throwing at the bid. (Accumulation) is in full effect.
3/ ADX & Directional Movement (+DI/-DI) .The ADX is beginning to trend upward from the 20 level, signaling that a new, powerful trend is being born. The +DI (Green) is firmly above the -DI (Red), meaning the bulls have officially seized control of the primary trend direction.
4/ Bollinger Band Compression .On the 1-hour chart (right), the Bollinger Bands are "Squeezing" tighter than they have in weeks. In technical analysis, extreme compression always leads to extreme expansion. With the $9.00 Gamma Walllooming, the path of least resistance is up.
5/ Key Levels to Watch
Immediate Support: $8.40 (The line in the sand).
Pivot Resistance: $8.92 - $9.00 (The "Squeeze Trigger").
Target 1: $12.43 (Previous High).
The Verdict: We are in the "Quiet Before the Storm." The chart is a coiled spring, the indicators are bullish, and the shorts are trapped against a wall of technical support. The technicals have officially converged with the science.
$IBRX- IBRX Shorts Intelligence Report – March 18, 2026
The shorts are officially out of oxygen. The data from today's session reveals a complete exhaustion of available liquidity. $IBRX. Screenshots attached.
1/ Zero Share Availability. As of 3:13 PM EST, IBKR availability hit N/A (Zero). We watched the borrowable pool dwindle from thousands to just 4 shares before it vanished entirely. The Fact: Shorts no longer have the "firepower" to suppress the bid. They are now playing pure defense.
2/ The Utilization Ceiling Live Ortex data confirms Utilization is at 91% - 100%. Nearly every single share that can be loaned out is already being used to short this stock. There is no "secondary reserve." If a large institution recalls their shares tonight, the shorts are forced into an immediate, non-negotiable buy-back.
3/ Cost to Borrow (CTB) .Heat The average CTB is sitting at 11.77%, with a Max spike of 23.38%. Shorts are paying double-digit interest rates to hold a losing position against a tide of NCCN and Saudi news. This "bleed" accelerates the timeline for Margin Calls.
4/ The Liquidity Trap (Days to Cover). With 132.34 Million shares short (34.90% of the float), the Days to Cover is 3.86. Translation: If an 8-K drops, it would take nearly four full trading days of average volume for every short to exit. They are trapped in a revolving door, and the door is jamming.
5/ Today’s Defensive Stunt. Despite the news, shorts added 2.07 million shares to their net position today. They spent their final "ammo" trying to defend the $9.00 Gamma Wall. The Result: They failed to crush the price, we held the $8.50 floor, and now they have Zero shares left to borrow for tomorrow’s open.
The Verdict: The "Spring" is fully coiled. The shorts are all-in, out of ammo, and facing a 4-day exit queue. Any gap-up tomorrow becomes a vertical flight.
$IBRX- IBRX Options Intelligence Report – March 18, 2026- March 18th 2026. Data included below.
The fuse is lit. The options market is currently pricing in a massive "Gamma Event" for the Friday expiration. $IBRX
1/ The $9.00 Gamma Wall -Today’s data confirms the largest concentration of Open Interest is sitting at the $9.00 Strike for this Friday (Mar 20).
Current OI: 27,670 Call contracts.
The Mechanics: If we cross $9.00, Market Makers must "delta-hedge" by buying millions of shares, creating a feedback loop of vertical price action.
2/ Unusual Institutional Flow.We tracked two "Smart Money" alerts today that indicate this isn't just a retail trade:
8:40 AM: A massive 2,029 Call Block was bought for the April 16th $10 Strike.
9:29 AM: Multiple Bullish Sweeps hit the tape, signaling institutions are bypassing limit orders to get long immediately. They aren't waiting for the 8-K; they are front-running it.
3/ The Put/Call Extremity The Volume Put/Call Ratio (PCR) finished today at an astonishing 0.09.
Interpretation: For every 1 Put traded, there were over 11 Calls bought. Bearish protection has completely evaporated. The market is positioned 100% for a "Binary Breakout."
4/ Expected Move & Max Pain
Max Pain: Currently sitting at $9.00.
Expected Move: The options market is pricing in a ±12% swing ($1.00+) by Friday's close.
The Divergence: While Max Pain is $9.00, the "Institutional Sweeps" are targeting $10.00+, suggesting the "Pain" will be felt entirely by the shorts.
The floor is set. The ceiling is thinning.
$IBRX- Congrats Dr PSS. @DrPatrick
The Scientific Convergence is Here. -$IBRX
1/ The Breakthrough Rockefeller University just published a landmark study (Mar 16, 2026) showing that a single tumor injection can trigger a "Vaccine Factory" that kills metastatic cancer body-wide. The research confirms that activating the IL-15 pathway is the key to unlocking this systemic response. [Link: sciencedaily.com/releases/20…]
2/ The Clinical Reality .This isn't just a lab theory. We've seen the brain scans on NewsNation. We’ve seen the QUILT-3.078 data: 19/23 Glioblastoma patients still alive as of Jan 2026. ANKTIVA is the first FDA-approved IL-15 agonist the exact "fuel" the Rockefeller scientists are calling for.
3/ Data Point: The "IL-15 Synergy" The Rockefeller study (antibody 2141-V11) confirms that CD40 therapy is most effective when paired with exogenous IL-15. Why? CD40 "activates" the immune cells, but IL-15 (ANKTIVA) "multiplies" them. It’s the difference between a single soldier and an entire army.
4/ Data Point: The "TLS" Command Center The research proved that this treatment creates Tertiary Lymphoid Structures (TLS) internal "immune command centers" inside the tumor. This explains the long-term durable responses seen in $IBRX trials. We aren't just killing cells; we are re-training the body to hunt cancer forever.
5/ The 1-2-3 Punch
Yesterday: $IBRX secured NCCN 2026 Guideline status (Commercial Floor).
Today: Global research validates the platform (Scientific Ceiling).
Imminent: The Saudi shipment lands (Operational Execution).
Pleased with the NCCN guidelines for Papillary only disease in non-muscle invasive bladder cancer (NMIBC). Validates the publication in Journal of Urology.
Now next step is to provide BCG for all patients who could benefit in bladder cancer.
pubmed.ncbi.nlm.nih.gov/4095…
$IBRX- Under the Hood of the $IBRX "Shakeout"
Yesterday was a hard day. We saw a massive gap to $9.30 on confirmed NCCN news, only to see the "Algos" and shorts slam it back to red by the close. If you only look at the price, you're missing the war.
Let’s look under the hood.
1. The "Naked" Short Attack Yesterday, $IBRX traded 28.6M shares. Forensic scan shows that shorts didn't exit they doubled down at the $9.30 peak to prevent a $10 Gamma Squeeze.
Current Short Interest: ~132M shares.
The Trap: They "spent" their ammunition to turn the screen red, but they couldn't break the $7.81 floor. They are now more over-leveraged than they were on Monday.
2. Liquidity is GONE Look at the latest IBKR data: 4 shares available to borrow. Not 4,000. Four. Utilization is pegged at the ceiling. There is no more "ammo" to suppress the next leg up. When the Saudi 8-K drops, there is no one left to sell only millions of shorts forced to buy.
3. The Saudi "Delay" is a Logistical Fact CEO Richard Adcock just confirmed at the Citizens Conference:
Shipments were delayed by regional conflict/airspace closures.
CRITICAL: Product is READY and they have now received AIRSPACE CLEARANCE. The "60-day" window wasn't a failure of execution; it was a physical flight delay that is now RESOLVED.
4. The Bottom Line The NCCN update (Step 1) is a permanent fundamental win for insurance revenue. The Saudi Shipment (Step 2) is now cleared for takeoff.
$IBRX #IBRX #ImmunityBio #ShortSqueeze
$IBRX- The update: Adcock confirmed product is READY and crucially they have now received AIRSPACE CLEARANCE. The planes are moving. The 60-day window was 'missed' by 72 hours because of a war, not a lack of execution. The 'Second Shoe' is in the air.
marketbeat.com/instant-alert…
$IBRX- Fact-Checking the Saudi Launch
$IBRX Saudi Launch & The 60-Day Clock
There is confusion about the "March 15 deadline." Let’s look at the verified SEC data and SFDA regulatory mandates that anchor this timeline.
1- The Regulatory Anchor (Jan 14, 2026) The Saudi Food and Drug Authority (SFDA) granted Accelerated Approval for ANKTIVA + Checkpoint Inhibitors in metastatic NSCLC (Lung Cancer).
Fact: This is a global first. KSA is currently the only jurisdiction on Earth authorized for this life-saving indication.+
SEC Verification: In the Feb 23, 2026, Form 8-K (Exhibit 99.1), ImmunityBio explicitly stated: "Commercial launch in Saudi Arabia is planned within 60 days of approval."
The Math: 60 days from Jan 14 = March 15, 2026.
2- The Pricing Certificate (Feb 20, 2026) Commercialization cannot happen without a price.
Fact: On Feb 20, IBRX confirmed: "The Registration Certificate of Pharmaceutical Product with pricing has been issued to ImmunityBio from the Saudi FDA."
Impact: This certificate is the legal "Green Light" for the first commercial sale and distribution.
3- Industrial Infrastructure: Cigalah & BioPharma This is a "State-Level" launch. IBRX established a wholly-owned Saudi subsidiary and partnered with Cigalah Healthcare (Naghi & Sons Group).
Reliability: Cigalah is a $2B+ distribution giant. CEO Rich Adcock confirmed on March 3: "Product shipments were ready to commence."
Strategy: Working directly with the Ministry of Investment (MISA) to bypass standard global supply bottlenecks.
4- The "Material Event" Filing (The 8-K): Under SEC rules, a "First International Commercial Sale" is a material event.
The Squeeze: 132M shares are short with 100% utilization. A Form 8-K dropping Sunday/Monday confirming the shipment turns "hope" into "verified revenue."
Bottom Line: The March 15 date isn't a guess it’s the regulatory deadline cited in sworn financial documents. The transition from R&D to Global Powerhouse is happening now.
#IBRX #ANKTIVA #SaudiVision2030 #Biotech #ShortSqueeze
Links for Reference
Feb 23 SEC 8-K: 700% Revenue Growth & Saudi Launch Timeline
ir.immunitybio.com/news-rele…
Feb 20 Press Release: SFDA Pricing Certificate & Cigalah Partnership
ir.immunitybio.com/news-rele…
Jan 14 Press Release: World-First Lung Cancer Approval
ir.immunitybio.com/news-rele…
$IBRX- Fact-Checking the Saudi Launch
$IBRX Saudi Launch & The 60-Day Clock
There is confusion about the "March 15 deadline." Let’s look at the verified SEC data and SFDA regulatory mandates that anchor this timeline.
1- The Regulatory Anchor (Jan 14, 2026) The Saudi Food and Drug Authority (SFDA) granted Accelerated Approval for ANKTIVA + Checkpoint Inhibitors in metastatic NSCLC (Lung Cancer).
Fact: This is a global first. KSA is currently the only jurisdiction on Earth authorized for this life-saving indication.+
SEC Verification: In the Feb 23, 2026, Form 8-K (Exhibit 99.1), ImmunityBio explicitly stated: "Commercial launch in Saudi Arabia is planned within 60 days of approval."
The Math: 60 days from Jan 14 = March 15, 2026.
2- The Pricing Certificate (Feb 20, 2026) Commercialization cannot happen without a price.
Fact: On Feb 20, IBRX confirmed: "The Registration Certificate of Pharmaceutical Product with pricing has been issued to ImmunityBio from the Saudi FDA."
Impact: This certificate is the legal "Green Light" for the first commercial sale and distribution.
3- Industrial Infrastructure: Cigalah & BioPharma This is a "State-Level" launch. IBRX established a wholly-owned Saudi subsidiary and partnered with Cigalah Healthcare (Naghi & Sons Group).
Reliability: Cigalah is a $2B+ distribution giant. CEO Rich Adcock confirmed on March 3: "Product shipments were ready to commence."
Strategy: Working directly with the Ministry of Investment (MISA) to bypass standard global supply bottlenecks.
4- The "Material Event" Filing (The 8-K): Under SEC rules, a "First International Commercial Sale" is a material event.
The Squeeze: 132M shares are short with 100% utilization. A Form 8-K dropping Sunday/Monday confirming the shipment turns "hope" into "verified revenue."
Bottom Line: The March 15 date isn't a guess it’s the regulatory deadline cited in sworn financial documents. The transition from R&D to Global Powerhouse is happening now.
#IBRX #ANKTIVA #SaudiVision2030 #Biotech #ShortSqueeze
Links for Reference
Feb 23 SEC 8-K: 700% Revenue Growth & Saudi Launch Timeline
ir.immunitybio.com/news-rele…
Feb 20 Press Release: SFDA Pricing Certificate & Cigalah Partnership
ir.immunitybio.com/news-rele…
Jan 14 Press Release: World-First Lung Cancer Approval
ir.immunitybio.com/news-rele…
$KINS- The Forensic Case for $KINS: Fundamentals vs. Activism
Headline: A data-driven breakdown of the $KINS "Value Gap." Why record earnings and a 13D filing are creating a unique liquidity event.
1/ The Earnings Baseline ($2.88 EPS) -Kingstone ($KINS) isn't just "improving"; it’s hitting historical peaks.
FY 2025 EPS: $2.88 (Diluted)
Net Income: $40.8M
Combined Ratio: 64.2% (Q4)
P/E Ratio: 5.3x (vs. industry avg 12x-15x). The company is trading at a significant discount to its peer group despite a 43% ROE.
2/ The Activist Catalyst (March 12) -The Fortunoff Group flipped from a passive 13G to an Active 13D filing.
Stake: 7.6% (1.1M shares).
Demand: A formal "Strategic Sale" process.
Support: Fortunoff holds 90,400 call options at the $15 strike. This creates a mechanical "floor" as market makers must hedge these ITM calls, absorbing sell-side liquidity.
3/ Management’s Defensive Signaling Within 24 hours of the activist filing, @KingstoneKINS began a proactive social media campaign:
Message: Signaling a path to $500M in direct premiums by 2029.
Focus: Entry into the California market in Q2 2026.
The Read: This is classic "X Diplomacy." Management is anchoring the valuation high to force any potential bidder to pay a massive premium for future growth rather than current price.
4/ The Convergence Timeline
Feb 2026: Record FY results prove structural profitability.
Mar 12: Activist 13D demands a sale.
Mar 13: Management counters with long-term "Independence" goals.
Next 72 Hours: The Board's formal response is the key catalyst. Historically, these acknowledgments trigger "Wolf Pack" institutional buying.
5/ The Outlook (Next 2–3 Weeks)- The "Technical V-Shape" is in motion.
Immediate Resistance: $16.17 (50-Day EMA).
Gap Fill Target: $16.80 – $17.14. With high insider ownership and a rare NY license, any buyout rumor could accelerate the stock toward its $21.50 analyst consensus.
Conclusion: We are seeing a clash between "Growth at any price" (Management) and "Exit now for value" (Activist). In either scenario, the current 5.3x P/E looks structurally unsustainable.
Watching the tape for institutional block trades. #ValueInvesting #KINS #Insurance #Activism
479
$IBRX-Here is the breakdown of the PSS post and the best way to understand it.
1. The "Special Forces" Analogy (The Clinical Edge)
The Message: Most cancer treatments (like chemo) are "carpet bombs" that damage everything. ANKTIVA is "Special Forces" it specifically recruits and arms NK Cells and Killer T-Cells.
Key Stat: Highlight the Hazard Ratio (HR) of 0.4 for duration of response. This means ANKTIVA-treated patients have a 60% lower risk of cancer returning compared to the standard of care.
2. The "Leonardo" Connection (The Industrial Edge)
The Message: PSS is "connecting the dots" between the science and the machine. The NANT Leonardo AI-robotic platform is the factory that makes the "Special Forces."
The 1:10 Shift: This is your strongest data point. 1:10 donor-to-dose ratio is no longer a theory it’s a robotic reality that scales globally.
3. Global Geopolitical Signaling
The Message: PSS is signaling that while the US regulatory path is a "fight," the rest of the world (starting with the March 15 Saudi Launch) is already embracing the future.
The "Enlightenment": He is essentially saying the "BioShield" isn't just a drug; it’s a global infrastructure for cancer care.
4. European Validation (EAU26)
The timing of this post, coinciding with the EAU26 (European Association of Urology) congress in London, is a signal of geographical expansion.
Global Standard: He is signaling that European clinicians now "understand" that ANKTIVA is not just a secondary treatment but a foundational "Special Forces" unit that can cure cancer by activating the innate and adaptive immune systems simultaneously.
5. Slide in the background
The slide in the background of his post emphasizes Key Mechanisms:
Long-term Memory: One of the most important signals here is "Promotes durable immune memory without exhaustion."
The Message to Shorts: This is a direct counter-narrative to those betting on short-term results. PSS is signaling that ANKTIVA creates a permanent internal defense system (Memory T cells), which is the key to the "curative" potential he mentions.
THE ENLIGHTENMENT HAS BEGUN. Dr. Patrick Soon-Shiong (@DrPatSoonShiong) just validated the "Leonardo" robotic thesis. This isn't just a biotech story; it's an industrial revolution. Special Forces: ANKTIVA recruits the elite killers (NK & T-cells) to seek and destroy, while ignoring "Tregs" (the tumor’s shield). Leonardo Robotics: The AI-driven backbone enabling the 1:10 dose yieldand 90% COGS reduction. Global Access: "Certain countries" are already moving. The Saudi launch on March 15 is just the start.Standard of Care is being disrupted in real-time. #IBRX #ANKTIVA #Immunotherapy #ShortSqueeze
This quoted post is unavailable.
$IBRX- Today, Friday, March 13, 2026, was indeed a pivotal day for ImmunityBio (IBRX). The stock surged over 10% to close near $8.91 at one point during the day and settled down around $8.40, effectively breaking a "7 out 8 day red streak" and reversing a sharp technical decline.
The excitement stems from a "perfect storm" of three massive catalysts that hit the wire simultaneously, directly addressing the biggest fears investors had about the company's future.
1. The "World Bank of NK Cells" (Manufacturing Milestone)
The primary driver for today's move was the announcement that ImmunityBio has successfully industrialized its cell therapy production.
The Scale: A single donor collection can now yield 5 billion highly pure NK cells.
The "1:10 Math": This provides 8 to 10 therapeutic doses per patient with a 12-day turnaround. This effectively "fixes" the business model by drastically lowering the cost of production and proving the company can scale globally.
The Goal: Dr. Patrick Soon-Shiong described this as the foundation for a "World Bank of Natural Killer Cells,"where treatments can be universally donated without the need for complex HLA matching.
2. The Saudi Arabia "Fuse" (March 15 Deadline)
The market is currently pricing in the March 15th Saudi Launch deadline (this Sunday).
Launch Confirmation: Today's manufacturing news serves as the "logistical proof" that ImmunityBio can actually supply the Middle East.
Lung Cancer Edge: Saudi Arabia is the first country in the world to approve ANKTIVA for Lung Cancer (NSCLC). The partnership with Cigalah Healthcare is expected to trigger revenue-generating shipments starting this weekend.
3-Outpatient Safety = Massive TAM Expansion
This is the single biggest "hidden" catalyst for the Saudi Arabia launch.
The Data: QUILT-3.076 Phase 1 results: 0% Grade 4/5 Adverse Events and 0% Cytokine Storm.
The Impact: Traditional CAR-T often requires 7–14 days of inpatient hospitalization due to toxicity risk. ImmunityBio’s 100% outpatient safety profile allows the drug to be administered in local clinics, expanding the Total Addressable Market (TAM) to the 80% of patients who don't live near specialized "certified" hospitals.
4-Cracking the "Checkpoint Resistance" Code
This addresses why they are a "Universal Backbone."
The Data: NCI-led preclinical data (March 2026) showed a p<0.0001 increase in MHC-Class I expression.
The Impact: 62% of neuroendocrine tumors (like SCLC) are "invisible" to current drugs because they lack MHC-I. By "turning the lights on," ImmunityBio isn't just treating cancer; it is sensitizing tumors so that every other immunotherapy (like Keytruda or Opdivo) can finally work.
Lets see what next week brings.. But closing green was a good sign. But as always no-one what happens next only Market knows.. So we continue to speculate and use the data publicly available to analyze .#ImmunityBio #ANKTIVA #Biotech
$IBRX- Dark pool data analysis.. This is a hard analysis.. But trying to share it with you all if it helps..
The $IBRX Dark Pool "X-Ray" (March 11, 2026)
6 red days on the lit exchange, but the Dark Pool tells a completely different story. If you’re feeling beaten up, you need to see the institutional footprints they’re trying to hide.
1- The "Off-Exchange" Shadow .Over the last 6 days, Off-Exchange (Dark Pool) Short Volume has reached extreme levels, peaking at 35.3% to 58.5% of daily volume.
The Reality: More than half of the selling pressure isn't coming from actual shareholders it's being "manufactured" in the dark to suppress the price without letting buy-side demand reflect on the public ticker.
2- Bullish Dark Pool Divergence. While the public price was sliding toward $8.00, the After-Hours VWAP and Dark Pool Prints have consistently trended higher.
The "Tell": Whales are using the cover of darkness to accumulate at $8.05–$8.20 while the "lit" price is painted red. This is the classic signature of Institutional Absorption. They are catching the shares retail drops.
3- The 20K "Ammo" Alert The most critical data point tonight? IBKR Borrow Availability just hit 20,000 shares.
The Context: For a stock with a 134.7M share short position, 20k is effectively ZERO.
The Squeeze: Shorts have exhausted their ammunition to defend the $8.00 floor. With 100% utilization, they are now "naked" and trapped heading into the Sunday launch window.
4- The "Spring" is Coiled Short Interest is pinned at 35.5% with 5.09 Days to Cover.
The Math: Dark pool data shows they haven't covered; they've only "rolled" their positions. When the March 15th Saudi news hits the tape, there is no "dark" exit big enough for 134 million shares.
Bottom Line: The red candles are for us ; the dark pool accumulation is for them.
#IBRX #ANKTIVA #DarkPool






























